Pharmacogenetic Approaches to Personalized SSRI Therapy

Authors

  • Aadi Balsaraf Student

DOI:

https://doi.org/10.5195/pur.2026.192

Abstract

A complicated interaction of pharmacokinetic (PK), pharmacodynamic (PD), genetic, and epigenetic factors influences inter-individual variability in response to selective serotonin reuptake inhibitors (SSRIs). This review summarizes recent findings in antidepressant pharmacogenetics, emphasizing the functions of important pharmacodynamic loci (SLC6A4, HTR2A, BDNF, ABCB1) and metabolic genes (CYP2C19, CYP2D6) in regulating drug exposure, efficacy, and tolerability. Evidence from observational studies and previous reports suggests that pharmacogenomic-guided therapy may improve treatment outcomes, especially for individuals with abnormal metabolic profiles or treatment resistance. Major obstacles to clinical translation include small effect sizes, population-specific heterogeneity, retrospective studies, and uneven integration with therapeutic drug monitoring. Additional implementation barriers include workflow integration, patient access, cost, and clinical education. To optimize the clinical impact of precision psychiatry, future research should focus on prospective, multicenter trials with diverse populations, standardized clinical decision frameworks, and integration of polygenic, epigenetic, and environmental data. This review investigates whether integrating pharmacogenomic information into SSRI prescribing can enhance treatment outcomes and reduce adverse events.

Author Biography

Aadi Balsaraf, Student

Aadi Balsaraf is a junior and first-year PharmD student at the University of Pittsburgh School of Pharmacy. He conducts research at the Center for Pharmacogenetics and is interested in drug development and academia.

References

Campos, Adrian I., Enda M. Byrne, Brittany L. Mitchell, et al. 2022. “Impact of CYP2C19 Metaboliser Status on SSRI Response: A Retrospective Study of 9500 Participants of the Australian Genetics of Depression Study.” The Pharmacogenomics Journal 22 (2): 130–35. https://doi.org/10.1038/s41397-022-00267-7.

Grant, Caroline W., Karina Delaney, Linsey E. Jackson, et al. 2025. “Comprehensive Characterization of Antidepressant Pharmacogenetics: A Systematic Review of Studies in Major Depressive Disorder.” Clinical and Translational Science 18 (6): e70255. https://doi.org/10.1111/cts.70255.

Jameson, Adam, Beth Fylan, Greg C. Bristow, et al. 2021. “What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings?” Frontiers in Genetics 12 (September). https://doi.org/10.3389/fgene.2021.740216.

Lorvellec, Marie-Agnès, Gilles Sipahimalani, Bertrand Lahutte, Hervé Delacour, Antoine Baldacci, and Emeric Saguin. 2024. “Pharmacogenetics Testing for Poor Response to Antidepressants: A Transnosographic Case Series.” Frontiers in Pharmacology 15 (October). https://doi.org/10.3389/fphar.2024.1440523.

Murphy, Greer M., Charlotte Kremer, Heidi E. Rodrigues, and Alan F. Schatzberg. 2003. “Pharmacogenetics of Antidepressant Medication Intolerance.” American Journal of Psychiatry 160 (October): 1830–35. https://doi.org/10.1176/appi.ajp.160.10.1830.

Porcelli, Stefano, Antonio Drago, Chiara Fabbri, Sara Gibiino, Raffaella Calati, and Alessandro Serretti. 2011. “Pharmacogenetics of Antidepressant Response.” Journal of Psychiatry and Neuroscience 36 (2): 87–113. https://doi.org/10.1503/jpn.100059.

Radosavljevic, Milica, Dubravka Svob Strac, Jasna Jancic, and Janko Samardzic. 2023. “The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy.” Genes 14 (5): 1095. https://doi.org/10.3390/genes14051095.

Sreeja, V., Anju Jose, Shashikant Patel, Bindu Menon, K. V. Athira, and Sumana Chakravarty. 2024. “Pharmacogenetics of Selective Serotonin Reuptake Inhibitors (SSRI): A Serotonin Reuptake Transporter (SERT)-Based Approach.” Neurochemistry International 173 (February): 105672. https://doi.org/10.1016/j.neuint.2023.105672.

Xu, Lei, Liyin Li, Qiutang Wang, Bing Pan, Leilei Zheng, and Zheng Lin. 2024. “Effect of Pharmacogenomic Testing on the Clinical Treatment of Patients with Depressive Disorder: A Randomized Clinical Trial.” Journal of Affective Disorders 359 (August): 117–24. https://doi.org/10.1016/j.jad.2024.05.063.

Zhang, Ying, and Weihua Yue. 2025. “Optimization of Antidepressant Treatment by Pharmacogenomics: A Case Report.” BMC Psychiatry 25 (1): 34. https://doi.org/10.1186/s12888-025-06481-4.

Downloads

Published

2026-11-16

How to Cite

Balsaraf, A. (2026). Pharmacogenetic Approaches to Personalized SSRI Therapy . Pittsburgh Undergraduate Review, 5(2). https://doi.org/10.5195/pur.2026.192